Abstract
Introduction
Neurodegeneration with brain iron accumulation (NBIA) is a wide number of neurodegenerative disorders characterized by iron accumulation in the brain, especially basal ganglia, substantia nigari, hippocampus and cerebellar nuclei. 1, 2 The typical presentation of NBIA disorder includes dystonia, Parkinsonism, choreoathetosis, mental dysfunction, spasticity, visual disturbance and bulbar dysfunction. 3 The most common form of NBIA is PKAN also known as NBIA-1 that is an autosomal recessive disorder characterized by a mutation in the PANK 2 at locus 20 P12. 3 This disease also has various psychiatry symptoms. [4] [5] [6] This review aims to describe the clinical manifestation, pathophysiology and the treatment of PKAN disease.
Materials and Methods

Etiology
The iron normally accumulated in the basal ganglia, hippocampus, cerebellar nuclei and another subcortical region. 7 The PKAN characterized by a mutation in the PANK 2 that codes the pantothenate kinase 2. Mutations are missense, duplication, deletion, splice site mutation and deletion of exon. 8 This protein kinase is responsible for the phosphorylation of pantothenate and this product combine with cysteine. The cysteine increase in the globus pallidus of patients with PKAN that in association with iron produce free radicals and cell damage. 9, 10 The Mutations of PANK2 also found in patients with HARP (hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration). The HARP is rare disease and has mental decline, abnormal movement and vision loss. 11
Diagnosis
Today, the PKAN disease is diagnosed by magnetic resonance imaging and confirmed with the genetic test. 12 Susceptibility weighted imaging (SWI) and field dependent R2 increase (FDRI) are the choice methods for the diagnosis of this disease and FDRI is more sensitive than SWI for detection of brain iron. 13 We can also use the cranial sonography that detects the over load of iron in midbrain. 14 The hallmark of this disease in the BRAIN MRI is eye of the tiger sign. The eye of the tiger is a hyperintense lesion surrounded by hypointensity in the medial aspect of bilateral globus pallidus on T2-weighted MRI. Central hyperintensity shows gliosis in globus pallidus and the surrounding hypointensity showing iron deposition (Figures 1 and 2 ). 15 All of the patients with eye-of-the-tiger sign don't have PANK2 mutation, Streckera et al. report a patient with multiple system atrophy (MSA) and systemic lupus erythematodes that has typical Eye of the Tiger sign in T2-weighted MRI. 16 Chaw-Liang Chang also reported a patient with cervical dystonia that has Eye of the Tiger without evidence of PANK2 gene mutation. 17 This sign also reported in a patient with mitochondrial membrane protein associatedneurodegeneration (MPAN). 18 The brain MRI may be normal in the Early Stages of Classic Pantothenate Kinase Associated Neurodegeneration and after the progression of disease, the Eye of the Tiger sign appear. 19 
Classification and presentations
It separated into classic and atypical form. The classic form starts in early childhood with rapid progression of symptoms including Parkinsonism, dystonia, cognitive decline and dementia, dysarthria, spasticity, seizure, optic atrophy, pigmentary retinopathy that disable the patient very sever. Atypical form of disease has later onset and less common than classic form and it may not be recognized by aging and has milder symptoms with slow progression in compared to classic type. 20, 21 The neuropsychiatric disorder includes ObsessiveCompulsive Disorder (OCD) , depression and schizophrenia-like psychosis. 22 In study that assessed the Intellectual and adaptive behavior functioning 16 children and adults with PKAN, there is varied cognitive expression, also there was an inverse correlation between the onset of the disease and the cognitive impairment. 23 The ophthalmologic manifestation is variable and includes saccadic pursuits, convergence impairment, vertical hypermetric saccades, square wave jerks and pigmentary retinopathy. 24 
Treatment Medications
for PKAN patients and different available drugs don't effect on disease progression. 25 Dystonia can be profoundly disabling in the affected patients and progresses over time and involves many parts of the body. It usually treated with anticholinergics, botulinum toxin, Oral and Intrathecal baclofen, benzodiazepines, Clonidine, gabapentin, pregabalin, tetrabenazine and other antispasticity drugs, alone or in combination. 26, 27 Vitamin B5 (pantothenate) may be able to improve PKAN patients by increasing levels of CoA and recovery of mitochondrial dysfunction. In mouse models of PKAN with a high-fat ketogenic diet, this drug was able to prevent some neurological symptoms, But to investigate its effects, clinical trial studies should be conducted in the future. [28] [29] [30] Surgery Surgical procedures such as Deep brain stimulation are now used for PKAN disease.The benefit effect of Deep brain stimulation, can occur quickly after surgery, But due to the progressive nature of the disease, symptoms may reappear after a while and the disease progresses again. 31, 32 In addition to Deep brain stimulation, other surgical procedures including Ablative pallidotomy or thalmotomy can also be used, although these surgical procedures are currently less commonly used and replaced by Deep brain stimulation. 33 In PKAN patients that have severe dystonia, spasticity and pain, intrathecal baclofen (ITB) pump can alleviate the symptoms. 34 Blair Ford et al. shows intrathecal baclofen is more effective if the dystonia is associated with spasticity and pain 35 it can also use intraventricular. In a study of Albright et al on ten patients with severe generalized secondary and heredodegenerative dystonia, Intraventricular baclofen was effective on dystonia. 36 
Iron chelation
The drugs currently used include deferiprone, deferoxamine and deferasirox. 37 Nowadays, Deferiprone have attracted the attention of many researchers. It can cross the blood-brain barrier to remove iron and prevent its accumulation. 38, 39 In studies that investigated the effect of deferiprone on the NBIA patients, the use of this drug was safe and without adverse effects. In these studies, deferiprone reduced iron load in brain imaging and in clinical evaluations, variable results were obtained which requires further investigation in the future. 40 
